Patents Represented by Attorney, Agent or Law Firm Monte R. Browder
-
Patent number: 5668141Abstract: A tetracyclic compound of the formula: ##STR1## wherein A and the atoms to which it is attached comprise a pyridine ring selected from: ##STR2## wherein R.sup.1, R.sup.2, and R.sup.3 are specifically defined, which compounds are useful in the treatment of dopamine-related neurological, psychological and cardiovascular disorders as well as in the treatment of substance abuse and other addictive behavior disorders, cognitive impairment and attention deficit disorder, and methods for the preparation thereof.Type: GrantFiled: April 2, 1996Date of Patent: September 16, 1997Assignee: Abbott LaboratoriesInventors: Kazumi Shiosaki, Yu Gui Gu, Michael Michaelides
-
Patent number: 5665721Abstract: The present invention provides new heterocyclic substituted cyclopentane compounds that are useful in inhibiting adenosine kinase. The present invention also provides pharmaceutical compositions containing such compounds and methods of using such compounds for inhibiting adenosine kinase.Type: GrantFiled: June 7, 1995Date of Patent: September 9, 1997Assignee: Abbott LaboratoriesInventors: Shripad S. Bhagwat, Marlon Daniel Cowart
-
Patent number: 5665777Abstract: Compounds of formula ##STR1## or a pharmaceutically acceptable salt thereof inhibit matrix metalloproteinases and TNF.alpha. secretion and are useful in the treatment of inflammatory disease states. Also disclosed are matrix metalloproteinases and TNF.alpha. secretion inhibiting compositions and a method for inhibiting matrix metalloproteinases and TNF.alpha. secretion.Type: GrantFiled: November 14, 1995Date of Patent: September 9, 1997Assignee: Abbott LaboratoriesInventors: Stephen W. Fesik, James B. Summers, Jr., Steven K. Davidsen, George S. Sheppard, Douglas H. Steinman, George M. Carrera, Jr., Alan Florjancic, James H. Holms
-
Patent number: 5659037Abstract: A process for preparing a chiral tetracyclic compound of formula: ##STR1## wherein R is hydrogen or a C.sub.1 -C.sub.6 -alkyl group and Z is oxygen, sulfur or --CH.dbd.CH--, the compounds having uses as dopamine agonists. The process involves reacting a chiral starting material and subsequent chiral intermediates in a series of chirality-preserving synthetic reactions.Type: GrantFiled: June 5, 1995Date of Patent: August 19, 1997Assignee: Abbott LaboratoriesInventors: Paul P. Ehrlich, Michael R. Michaelides, Maureen A. McLaughlin, Chi-Nung Hsaio
-
Patent number: 5654305Abstract: The present invention provides compounds of formula ##STR1## wherein Y is >C.dbd.O or >S(O).sub.t wherein t is 1 or 2 and the pharmaceutically acceptable salts thereof which are potent antagonists of PAF and are useful in the treatment of PAF-related disorders including asthma, rhinitis, shock, respiratory distress syndrome, acute inflammation, transplanted organ rejection, gastrointestinal ulceration, allergic skin diseases, delayed cellular immunity, parturition, fetal lung maturation, and cellular differentiation.Type: GrantFiled: July 2, 1996Date of Patent: August 5, 1997Assignee: Abbott LaboratoriesInventors: George S. Sheppard, Steven K. Davidsen, James B. Summers, George M. Carrera, Jr.
-
Patent number: 5643922Abstract: The present invention provides compounds of formula ##STR1## and the pharmaceutically acceptable salts thereof which are potent antagonists of PAF and are useful in the treatment of PAF-related disorders including asthma, rhinitis, shock, respiratory distress syndrome, acute inflammation, transplanted organ rejection, gastrointestinal ulceration, allergic skin diseases, delayed cellular immunity, parturition, fetal lung maturation, and cellular differentiation.Type: GrantFiled: July 2, 1996Date of Patent: July 1, 1997Assignee: Abbott LaboratoriesInventors: George S. Sheppard, Steven K. Davidsen, James B. Summers
-
3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
Patent number: 5629325Abstract: Novel 3-pyridyloxymethyl heterocyclic ether compounds of the formula: ##STR1## or the pharmaceutically-acceptable salts or prodrugs thereof are selective and potent ligands at neuronal nicotinic cholinergic channel receptors, and are effective in controlling synaptic transmission.Type: GrantFiled: June 6, 1996Date of Patent: May 13, 1997Assignee: Abbott LaboratoriesInventors: Nan-Horng Lin, Yun He, Mark W. Holladay, Keith Ryther, Yihong Li -
Patent number: 5621133Abstract: Novel compounds having the formula ##STR1## and the pharmaceutically acceptable salts, esters and amides thereof, whereinA is --O--, --S-- or --CR.sup.2 R.sup.8 --;R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10, X and Y are specifically defined; andup to one combination of (a) R.sup.2 and R.sup.5, (b) R.sup.5 and R.sup.6, (c) R.sup.5 and R.sup.7, (d) R.sup.6 and R.sup.7, and (e) R.sup.7 and Y, taken together with the atoms to which they are attached, may form a ring, the compounds being useful for treating dopamine-related neurological, psychological and cardiovascular disorders as well as in the treatment of cognitive impairment, attention deficit disorder, and substance abuse and other addictive behavior disorders.Also disclosed are intermediates and processes useful in the preparation of the above compounds.Type: GrantFiled: June 5, 1995Date of Patent: April 15, 1997Inventors: Michael P. DeNinno, Richard J. Perner
-
Patent number: 5616596Abstract: The invention relates to compounds having activity to inhibit lipoxygenase enzyme activity, to pharmaceutical compositions comprising these compounds, and to a medical method of treating. More particularly, this invention concerns certain substituted arylalkynyl- and ((heteroaryl)alkynyl)-N-hydroxy-ureas which inhibit leukotriene biosynthesis, to pharmaceutical compositions of these compounds and to a method of inhibiting leukotriene biosynthesis.Type: GrantFiled: April 13, 1995Date of Patent: April 1, 1997Assignee: Abbott LaboratoriesInventors: Anwer Basha, Clint D. W. Brooks, Pramila Bhatia, Richard A. Craig, James D. Ratajczyk, Andrew O. Stewart
-
Patent number: 5597832Abstract: A tetracyclic compound of the formula: ##STR1## wherein A and the atoms to which it is attached and the optional double bond represent a mono- or di-heterocyclic ring selected from: ##STR2## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and X are specifically defined, which compounds are useful in the treatment of dopamine-related neurological, psychological and cardiovascular disorders as well as in the treatment of substance abuse and other addictive behavior disorders, cognitive impairment and attention deficit disorder.Type: GrantFiled: November 10, 1994Date of Patent: January 28, 1997Assignee: Abbott LaboratoriesInventors: Michael R. Michaelides, Yufeng Hong
-
Patent number: 5591884Abstract: Novel compounds having the formula ##STR1## and the pharmaceutically acceptable salts, esters and amides thereof, whereinA is --O--, --S-- or --CR.sup.2 R.sup.8 --;R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10, X and Y are specifically defined; andup to one combination of (a) R.sup.2 and R.sup.5, (b) R.sup.5 and R.sup.6, (c) R.sup.5 and R.sup.7, (d) R.sup.6 and R.sup.7, and (e) R.sup.7 and Y, taken together with the atoms to which they are attached, may form a ring, the compounds being useful for treating dopamine-related neurological, psychological and cardiovascular disorders as well as in the treatment of cognitive impairment, attention deficit disorder, and substance abuse and other addictive behavior disorders.Also disclosed are intermediates and processes useful in the preparation of the above compounds.Type: GrantFiled: June 5, 1995Date of Patent: January 7, 1997Assignee: Abbott LaboratoriesInventors: Michael P. DeNinno, Richard J. Perner
-
Patent number: 5446039Abstract: A method for the treatment of neurological disorders, comprising administering to a mammal in need of such treatment an effective amount of a compound of formula I or of formula II (formulae set out on pages following the Examples), whereinR.sup.1, R.sup.2, R.sup.3 and R.sup.4 are independently selected from:hydrogen,(1-3C)perfluoroalkyl,halo, nitro and cyano;R.sup.5 is a (1-5C)alkyl group;or a pharmaceutically acceptable salt thereof.Also provided are compounds and pharmaceutical compositions suitable for the treatment of neurological disorders.Type: GrantFiled: July 23, 1993Date of Patent: August 29, 1995Assignee: Imperial Chemical Industries, PLCInventors: Marc J. Chapdelaine, Charles D. McLaren
-
Patent number: 5441960Abstract: The present invention relates to certain novel substituted ketones which are 1-pyrimidinylacetamide derivatives of formula I, ##STR1## set out herein, which are inhibitors of human leukocyte elastase (HLE), also known as human neutrophil elastase (HNE), making them useful whenever such inhibition is desired, such as for research tools in pharmacological, diagnostic and related studies and in the treatment of diseases in mammals in which HLE is implicated. The invention also includes intermediates ##STR2## useful in the synthesis of these substituted ketones processes for preparing the substituted ketones pharmaceutical compositions containing such substituted ketones and methods for their use.Type: GrantFiled: April 8, 1993Date of Patent: August 15, 1995Assignee: Zeneca LimitedInventors: Peter R. Bernstein, Philip D. Edwards, Andrew Shaw, Royston M. Thomas, Chris A. Veale, Peter Warner, Donald J. Wolanin
-
Patent number: 5405852Abstract: The present invention relates to certain novel amide ##STR1## derivatives which are pyrido[3,4-b]indol-2-ylacetamides which are inhibitors of human leukocyte elastase (HLE), also known as human neutrophil elastase (HNE), making them useful whenever such inhibition is desired, such as for research tools in pharmacological, diagnostic and related studies and in the treatment of diseases in mammals in which HLE is implicated. The invention also includes intermediates useful in the synthesis of these amide derivatives, processes for preparing the amide derivatives, pharmaceutical compositions containing such amide derivatives and methods for their use.Type: GrantFiled: June 3, 1993Date of Patent: April 11, 1995Assignee: Zeneca LimitedInventors: Chris A. Veale, Peter Warner, Donald J. Wolanin
-
Patent number: 5399568Abstract: Compounds of formula I ##STR1## wherein X and Y are H or halo; R.sup.2 is: [structures Ia, Ib or Ic;] ##STR2## R.sup.3 is selected from unsubstituted or substituted alkyl, aryl or heteroaryl groups;R.sup.4 is selected from H or (Cl-6)alkyl,and pharmaceutically acceptable salts thereof, useful in the treatment of neuropsychiatric disoders such as psychoses; pharmaceutical compositions comprising a compound of formula I and a pharmaceutically acceptable diluent or carrier; and methods of treating neuropschiatric disorders comprising administering to a mammal (including man) in need of such treatment an effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: August 6, 1992Date of Patent: March 21, 1995Assignee: Imperial Chemical Industries plcInventors: Robert T. Jacobs, Cyrus J. Ohnmacht, Diane A. Trainor
-
Patent number: 5266570Abstract: Compounds of formula I, Ia or Ib and pharmaceutically acceptable salts thereof, useful in the treatment of neuropsychiatric disorders such as psychoses; pharmaceutical compositions comprising a compound of formula I and a pharmaceutically acceptable diluent or carrier; and methods of treating neuropschiatric disorders comprising administering to a mammal (including man) in need of such treatment an effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof; ##STR1##Type: GrantFiled: August 6, 1992Date of Patent: November 30, 1993Assignee: Imperial Chemical Industries PLCInventors: Ying K. Yee, Cyrus J. Ohnmacht, Diane A. Trainor, Joseph J. Lewis
-
Patent number: 5227490Abstract: Novel fibrinogen receptor antagonists of the formula ##STR1## are provided in which the claimed compounds exhibit fibrinogen receptor antagonist activity, inhibit platelet aggregation and are therefore useful in modulating thrombus formation.Type: GrantFiled: February 21, 1992Date of Patent: July 13, 1993Assignee: Merck & Co., Inc.Inventors: George D. Hartman, Wasyl Halczenko
-
Patent number: 5215894Abstract: The present invention is concerned with a novel biotransformation process for producing 17.beta.-N-monosubstituted carbamoyl-11-oxo-4-aza-5-.alpha.-androst-3-ones of the formula: ##STR1## These compounds are testosterone 5-.alpha. reductase inhibitors and are produced via a claimed novel biotransformation process using the green algae, Selenastrum capricornutum.Type: GrantFiled: February 25, 1992Date of Patent: June 1, 1993Assignee: Merck & Co., Inc.Inventors: Byron H. Arison, Josephine R. Carlin, Edamanal S. Venkataramani